Evotec AG Reports Mixed H1 2025 Performance

Evotec Ag (Adr) ( (EVO) ) has released its Q2 earnings. Here is a breakdown of the information Evotec Ag (Adr) presented to its investors.

Evotec AG (ADR) is a global biotechnology company based in Hamburg, Germany, specializing in drug discovery, development, and manufacturing services across various therapeutic areas. The company operates in the pharmaceutical and biotechnology sector, providing comprehensive solutions through its Discovery & Preclinical Development and Just – Evotec Biologics segments.

In its latest earnings report for the first half of 2025, Evotec AG reported a 5% decrease in group revenues to €371.2 million compared to the same period in 2024. The company highlighted a strategic shift in its revenue mix, with Just – Evotec Biologics showing strong growth, driven by higher demand, while the Discovery & Preclinical Development segment experienced softer demand.

Key financial metrics revealed that Just – Evotec Biologics achieved a 16% increase in revenues to €102.2 million, while Discovery & Preclinical Development saw an 11% decline to €269.0 million. The company maintained strong cost control, resulting in an adjusted Group EBITDA of €(1.9) million, aligning with expectations. Strategic collaborations with Bristol Myers Squibb in protein degradation and neuroscience have progressed, contributing to performance-based payments.

Looking forward, Evotec AG remains committed to its strategy for sustainable growth, with adjusted guidance for 2025 reaffirming expected group revenues between €760 – 800 million and an adjusted EBITDA of €30 – 50 million. The company anticipates a compound annual growth rate in revenues of 8 – 12% through 2028, with an EBITDA margin exceeding 20%.